Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 1,077 15 aug 2022 17:35
  • +0,058 (+5,69%) Dagrange 1,024 - 1,078
  • 11.203.918 Gem. (3M) 3,4M

Pharming april 2019

5.623 Posts
Pagina: «« 1 ... 70 71 72 73 74 ... 282 »» | Laatste | Omlaag ↓
  1. BioTics 5 april 2019 13:19
    quote:

    tombola schreef op 5 april 2019 13:16:

    We kunnen van mening verschillen over veel zaken, ik vind zwarte piet prima bijvoorbeeld, net als roetveegpieten, speel Sint samen met beiden, maar de mensen die mij een nok willen geven omdat ik onpasselijk word van het aanduiden van medemensen van een ander ras op een uiterlijk kenmerk, daarmee ga ik niet hierover discussieren. Ga lekker PVV of FvD stemmen, maar houd dit forum svp vrij van dit soort taal. Gelukkig zijn er die het hiermee eens zijn.
    Hallo,. Ga lekker PVV of FvD stemmen. Nou moet je niet gaan generaliseren he. foei.
  2. forum rang 6 Kompas 5 april 2019 13:42
    quote:

    BioTics schreef op 5 april 2019 13:36:

    waar hebben we dit aan te danken? dames/heren specialisten??
    Wellicht dan toch vertrouwen in het bereiken van de doelstellingen uit onderstaand vanuit Pharming afgegeven Outlook voor 2019 !!

    Outlook 2019

    For the remainder of 2019, the Company expects:

    Continued growth in revenues from sales of RUCONEST®, mainly driven by the US and Western Europe operations.

    Continued achievement of positive net earnings during the year.

    • Continued investment in the expansion of production of RUCONEST® in order to meet the growing demand for RUCONEST® internationally.

    • Investment in further clinical trial programs for RUCONEST® with low-volume concentrated liquid intramuscular and subcutaneous versions of RUCONEST® for both acute treatment and prophylaxis of HAE, as well as research into other more convenient routes of administration.

    • Investment in clinical trials to explore pre-eclampsia and acute kidney injury for RUCONEST®/rhC1INH.

    • Investment in development of the new pipeline programs in Pompe disease and Fabry’sdisease, and other new development opportunities and assets as these occur.

    • Increasing marketing activity where this can be profitable for Pharming, such as opening new countries for RUCONEST®.

    • We will continue to support all our teams and marketing partners in order to enable the maximization of the sales and distribution potential of RUCONEST® for patients in all territories, as we continue to believe that RUCONEST® represents a fast effective, reliable and safe therapy option to treat acute angioedema attacks in patients with HAE.
  3. forum rang 7 moneymaker_BX 5 april 2019 13:45
    quote:

    Kompas schreef op 5 april 2019 13:42:

    [...]

    Wellicht dan toch vertrouwen in het bereiken van de doelstellingen uit onderstaand vanuit Pharming afgegeven Outlook voor 2019 !!

    Outlook 2019

    For the remainder of 2019, the Company expects:

    Continued growth in revenues from sales of RUCONEST®, mainly driven by the US and Western Europe operations.

    Continued achievement of positive net earnings during the year.

    • Continued investment in the expansion of production of RUCONEST® in order to meet the growing demand for RUCONEST® internationally.

    • Investment in further clinical trial programs for RUCONEST® with low-volume concentrated liquid intramuscular and subcutaneous versions of RUCONEST® for both acute treatment and prophylaxis of HAE, as well as research into other more convenient routes of administration.

    • Investment in clinical trials to explore pre-eclampsia and acute kidney injury for RUCONEST®/rhC1INH.

    • Investment in development of the new pipeline programs in Pompe disease and Fabry’sdisease, and other new development opportunities and assets as these occur.

    • Increasing marketing activity where this can be profitable for Pharming, such as opening new countries for RUCONEST®.

    • We will continue to support all our teams and marketing partners in order to enable the maximization of the sales and distribution potential of RUCONEST® for patients in all territories, as we continue to believe that RUCONEST® represents a fast effective, reliable and safe therapy option to treat acute angioedema attacks in patients with HAE.

    Is dit vers van de pers
    Heeft Sijmen dit net zelf geplaatst?
5.623 Posts
Pagina: «« 1 ... 70 71 72 73 74 ... 282 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Pharming Group Meer »

Koers 1,077   Verschil +0,06 (+5,69%)
Laag 1,024   Volume 11.203.918
Hoog 1,078   Gem. Volume 3.398.939
15 aug 2022 17:35
Premium

Pharming óók nog actief op overnamejacht

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Ontdek IEX Premium

Gerelateerde Video's

  1. video thumbnail

    Outlook Pharming

    7 juni 2018 16:58 - Vimeo

  2. video thumbnail

    Pharming: Groeiperspectieven

    13 maart 2018 22:16 - Vimeo

  3. video thumbnail

    Pharming kan verder omhoog

    27 oktober 2017 17:23 - Vimeo

  4. video thumbnail

    Arend Jan Kamp over Pharming

    26 oktober 2017 13:24 - Vimeo

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links